Search for content, post, videos

Lynparza receives additional approval in the US

Sean Bohen
AstraZeneca and Merck & Co announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib). The approval is as follows: New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primar
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.